Cardiol Therapeutics Inc. Overview
Pro stress-test →Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.
Strategic Profile
Pro stress-test →Cardiol's therapeutic approach centers on modulating inflammasome pathway activation through pharmaceutically manufactured cannabidiol formulations developed under cGMP standards. The lead oral drug candidate, CardiolRx™, is in late-stage clinical development in Phase III MAVERIC trial for recurrent pericarditis and Phase II ARCHER trial for acute myocarditis, while also advancing CRD-38, a proprietary subcutaneous cannabidiol formulation for heart failure.
Competitive Landscape
Pro stress-test →Cardiol operates in the cardiovascular therapeutics space competing with established pharma companies developing heart disease treatments. The company differentiates through its cannabidiol-based approach targeting inflammasome pathways in conditions like pericarditis, myocarditis, and heart failure where treatment options are limited. Competitors include larger biopharmaceutical firms with cardiac pipelines and other inflammatory disease specialists.
Industry Context
Cardiol Therapeutics Inc. operates in Biopharmaceutical/Cardiovascular Therapeutics.
Key facts
Founded: 2017 · Headquarters: Toronto, Canada · Market cap: $246.81M CAD